Featured Research

from universities, journals, and other organizations

Patients' underlying health linked to worse outcomes for melanoma

Date:
August 30, 2011
Source:
University of Michigan Health System
Summary:
It's not how old but how frail patients are that can predict how well they will fare after a melanoma diagnosis. In fact, young patients in poor health may have worse outcomes than older patients in good shape.

It's not how old but how frail patients are that can predict how well they will fare after a melanoma diagnosis. In fact, young patients in poor health may have worse outcomes than older patients in good shape.

A new study from the University of Michigan Comprehensive Cancer Center finds that patients with decreased core muscle density were more likely to see their cancer spread to distant parts of the body.

These findings may also support the idea that the patient's biological response to a tumor is important in controlling the spread of melanoma. Patients whose systems are less able to mount a response may be more prone to their cancer spreading.

The researchers believe that identifying those patients who are at higher risk of poor outcomes could impact treatment decisions, including the success of new immunotherapy drugs. And potentially, if this degenerative muscle loss, called sarcopenia, can be reversed, patients might have better outcomes.

The study, which appears online in Annals of Surgical Oncology, looked at 101 patients treated for stage III melanoma at the U-M Comprehensive Cancer Center. Researchers examined CT scans for each patient to measure the area and density of a core muscle called the psoas, which runs along both sides of the spine.

They found that patients with lower muscle density had significantly higher rates of their cancer returning -- regardless of factors such as the size of the tumor or the patient's age. Every 10 units of decreased muscle density translated to a 28 percent increase in recurrence. In addition, frailer patients had more complications from surgery to remove their cancerous lymph nodes.

Research has previously linked older age to worse outcomes in melanoma. These new results distinguish that it's the underlying vitality of the patient, not age, that really matters.

Many studies have looked at ways to reverse sarcopenia by focusing on diet and exercise.

"The big question is if we could reverse sarcopenia through better nutrition and exercise, would that lead to a decreased risk of recurrence in those patients?" says lead study author Michael S. Sabel, M.D., associate professor of surgery at the U-M Medical School.

In addition, researchers hope this information will help explain the limited success of new immunotherapy or cancer vaccine treatments.

"The data suggests that frailer patients may be less likely to respond to these forms of therapy. It is very possible that prior trials of vaccines or other immune therapies that didn't show an effect would have shown an effect if we had weeded out the patients unlikely to respond to therapy," Sabel says.

Researchers plan next to look at CT scans from patients treated in these trials to analyze whether the treatments were more effective in patients without sarcopenia.

Melanoma statistics: 68,130 Americans will be diagnosed with melanoma this year and 8,700 will die from the disease, according to the American Cancer Society


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. Michael S. Sabel, Jay Lee, Shijie Cai, Michael J. Englesbe, Stephen Holcombe, Stewart Wang. Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma. Annals of Surgical Oncology, 2011; DOI: 10.1245/s10434-011-1976-9

Cite This Page:

University of Michigan Health System. "Patients' underlying health linked to worse outcomes for melanoma." ScienceDaily. ScienceDaily, 30 August 2011. <www.sciencedaily.com/releases/2011/08/110830102549.htm>.
University of Michigan Health System. (2011, August 30). Patients' underlying health linked to worse outcomes for melanoma. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/08/110830102549.htm
University of Michigan Health System. "Patients' underlying health linked to worse outcomes for melanoma." ScienceDaily. www.sciencedaily.com/releases/2011/08/110830102549.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins